GLAXO

Q4FY25 Highlights

Q4FY25 Highlights: Revenue stood at ₹966 crore, showing 6% like-to-like growth Profit After Tax (PAT) was ₹260 crore FY25 Highlights: Full-year revenue reached ₹3,723 crore, a growth of 9% PAT before exceptional items rose 32% to ₹915 crore EBITDA margin improved by 500 basis points to 31.4% Management Commentary: The company attributed its performance to a strong and diversified portfolio in General Medicines, Specialty, and Vaccines. Enhanced engagement with healthcare professionals and digital acceleration helped improve reach and customer experience. Key brands like Augmentin, Calpol, Ceftum, T-Bact, and Trelegy were major growth drivers. The Shingrix vaccine gained traction due to increased awareness and ecosystem development. Looking ahead, the company plans to focus on its innovative portfolio with upcoming oncology asset launches in FY26.